125I-radiolabeled morpholine-containing arginine-glycine- aspartate (RGD) ligand of α vβ 3 integrin as a molecular imaging probe for angiogenesis

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5024-5033

  Bianchini, Francesca ^a,b   Cini, Nicoletta ^c   Trabocchi, Andrea ^a   Bottoncetti, Anna ^c   Raspanti, Silvia ^a   Vanzi, Eleonora ^a   Menchi, Gloria ^a   Guarna, Antonio ^a   Pupi, Alberto ^a,b   Calorini, Lido ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; CILENGITIDE; GLYCINE; IODINE 125; MORPHOLINE; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; CYCLOPEPTIDE; LIGAND; MORPHOLINE DERIVATIVE; OLIGOPEPTIDE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL ADHESION; CELL MIGRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; IC 50; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA CELL; MOLECULAR DOCKING; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME; XENOGRAFT; CANCER TRANSPLANTATION; CELL MOTION; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; MELANOMA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SCINTISCANNING; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TISSUE DISTRIBUTION; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL ADHESION; CELL MOVEMENT; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; IODINE RADIOISOTOPES; LIGANDS; MELANOMA; MODELS, MOLECULAR; MOLECULAR PROBES; MORPHOLINES; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDES, CYCLIC; POSITRON EMISSION TOMOGRAPHY, COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84862270302     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2016232     Document Type: Article

References (49)

1. Challenges and Opportunities Report; U.S. Department of Health and Human Services, Food and Drug Administration: Silver Spring, MD, March 2004; http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunities-Reports-/ucm077262.htm.
2. Backgrounder: How New Drugs Move Through the Development and Approval Process; Tufts Center for the Study of Drug Development: Boston, November 1, 2001
3. Gilbert, J., Henske, P., and Singh, A. Rebuilding Big Pharma's Business Model. The Business & Medicine Report, Windhover Information, November 2003; Vol. 21, no. 10, http://www.bain.com/Images/rebuilding-big-pharma.pdf.
4. Innovative drug development approaches-project. Final report from THEEMEA/CHMP-THINK-TANK group on innovative drug development; EMEA 2007; pp 1-26, http://www.ema.europa.eu/docs/en-GB/document-library/Other/2009/10/ WC500004913.pdf.
5. Gilbert, M. R.; Kuhn, J.; Lamborn, K. R.; Lieberman, F.; Wen, P. Y.; Mehta, M.; Cloughesy, T.; Lassman, A. B.; Deangelis, L. M.; Chang, S.; Prados, M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery J. Neurooncol. 2012, 106, 147-153
6. Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC); National Institutes of Health: Bethesda, MD; http://clinicaltrials.gov/ct2/ show/NCT00689221, http://clinicaltrials.gov/ct2/show/NCT00085254.
7. Arnaout, M. A.; Mahalingam, B.; Xiong, J. P. Integrin structure, allostery, andbidirectional signaling Annu Rev. Cell Dev. Biol. 2005, 21, 381-410
8. Cabodi, S.; del Pilar Camacho-Leal, M.; Di Stefano, P.; Defilippi, P. Integrin signalling adaptors: not only figurants in the cancer story Nature Rev. Cancer 2010, 10, 858-870
9. Shattil, S. J.; Kim, C.; Ginsberg, M. H. The final steps of integrin activation: the end game Nature Rev. Mol. Cell Biol. 2010, 11, 288-300
10. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities Nature Rev. Cancer 2010, 10, 9-22
11. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-674
12. Albelda, S. M.; Mette, S. A.; Elder, D. E.; Stewart, R.; Damjanovich, L.; Herlyn, M.; Buck, C. A. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression Cancer Res. 1990, 50, 6757-6764
13. Seftor, R. E. Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression Am. J. Pathol. 1998, 153, 1347-1351
14. Van Belle, P. A.; Elenitsas, R.; Satyamoorthy, K.; Wolfe, J. T.; Guerry, D., IV; Schuchter, L.; Van Belle, T. J.; Albelda, S.; Tahin, P.; Herlyn, M.; Elder, D. E. Progression-related expression of beta3 integrin in melanomas and nevi Hum. Pathol. 1999, 30, 562-567
15. McGary, E. C.; Lev, D. C.; Bar-Eli, M. Cellular adhesion pathways and metastatic potential of human melanoma Cancer Biol. Ther. 2002, 1, 459-465
16. Brooks, P. C.; Strömblad, S.; Sanders, L. C.; von Schalscha, T, L.; Aimes, R. T.; Stetler-Stevenson, W. G.; Quigley, J. P.; Cheresh, D. A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 Cell 1996, 85, 683-693
17. Hofmann, U. B.; Westphal, J. R.; Waas, E. T.; Becker, J. C.; Ruiter, D. J.; van Muijen, G. N. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression J. Invest. Dermatol. 2000, 115, 625-632
18. Gálvez, B. G.; Matías-Román, S.; Yáñez-Mó, M.; Sánchez-Madrid, F.; Arroyo, A. G. ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells J. Cell Biol. 2002, 159, 509-521
19. Alonso, S. R.; Tracey, L.; Ortiz, P.; Pérez-Gómez, B.; Palacios, J.; Pollán, M.; Linares, J.; Serrano, S.; Sáez-Castillo, A. I.; Sánchez, L.; Pajares, R.; Sánchez-Aguilera, A.; Artiga, M. J.; Piris, M. A.; Rodríguez-Peralto, J. L. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis Cancer Res. 2007, 67, 3450-3460
20. Hynes, R. O. A reevaluation of integrins as regulators of angiogenesis Nature Med. 2002, 8, 918-921
21. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alpha(V)beta(3) integrin for a new cancer therapy Angew. Chem., Int. Ed. Engl. 1997, 36, 1374-1389
22. MacDonald, T. J.; Taga, T.; Shimada, H.; Tabrizi, P.; Zlokovic, B. V.; Cheresh, D. A.; Laug, W. E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist Neurosurgery 2001, 48, 151-157
23. Kumar, C. C.; Malkowski, M.; Yin, Z.; Tanghetti, E.; Yaremko, B.; Nechuta, T.; Varner, J.; Liu, M.; Smith, E. M.; Neustadt, B.; Presta, M.; Armstrong, L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrinreceptor antagonist Cancer Res. 2001, 61, 2232-2238
24. 3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts Cancer Res. 2002, 62, 4263-4272
25. Belvisi, L.; Riccioni, T.; Marcellini, M.; Vesci, L.; Chiarucci, I.; Efrati, D.; Potenza, D.; Scolastico, C.; Manzoni, L.; Lombardo, K.; Stasi, M. A.; Orlandi, A.; Ciucci, A.; Nico, B.; Ribatti, D.; Giannini, G.; Presta, M.; Carminati, P.; Pisano, C. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist Mol. Cancer Ther. 2005, 4, 1670-1680
26. Clezardin, P.; Teti, A. Bone metastasis: pathogenesis and therapeutic implications Clin. Exp. Metastasis. 2007, 24, 599-608
27. Trabocchi, A.; Menchi, G.; Cini, N.; Bianchini, F.; Raspanti, S.; Bottoncetti, A.; Pupi, A.; Calorini, L.; Guarna, A. Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis J. Med. Chem. 2010, 53, 7119-7128
28. Gentilucci, L.; Cardillo, G.; Spampinato, S.; Tolomelli, A.; Squassabia, F.; De Marco, R.; Bedini, A.; Baiula, M.; Belvisi, L.; Civera, M. Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partiallymodified retro-inverso cyclotetrapeptide mimetics J. Med. Chem. 2010, 53, 106-118
29. 3 Targeted Radiotracers for Tumor Imaging Mol. Pharmaceutics 2006, 3, 472-486
30. Beer, A. J.; Schwaiger, M. Imaging of integrin αvβ3 expression Cancer Metastasis Rev. 2008, 27, 631-644
31. Haubner, R.; Decristoforo, C. Radiolabelled RGD peptides and peptidomimetics for tumor targeting Front Biosci. 2009, 14, 872-886
32. 3-Targeted Radiotracers: Maximizing Binding Affinity via Bivalency Bioconjugate Chem. 2009, 20, 2199-2213
33. 3 Expression Theranostic 2011, 1, 48-57
34. Dijkgraaf, I.; Beer, A. J.; Wester, H. J. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression Front Biosci. 2009, 14, 887-899
35. 3-Integrin Expression in Vivo Acc. Chem. Res. 2009, 42, 969-980
36. Li, Z. B; Chen, X. MicroPET, MicroSPECT, and NIR Fluorescence Imaging of Biomolecules in Vivo Meth ods Mol. Biol. 2009, 544, 461-481
37. Zhou, Y.; Chakraborty, S.; Liu, S. Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT Theranostic 2011, 1, 58-62
38. Cini, N.; Trabocchi, A.; Menchi, G.; Bottoncetti, A.; Raspanti, S.; Pupi, A.; Guarna, A. Morpholine-based RGD-cyclopentapeptides as alphavbeta3/ alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity Bioorg. Med. Chem. 2009, 17, 1542-1549
39. Xiong, J. P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. Crystal Structure of the extracellular domain of integrin alphaV beta3 in complex with an Arg-Gly-Asp ligand Science 2002, 296, 151-155
40. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662
41. Benaron, D. A. The future of cancer imaging Cancer Metastasis Rev. 2002, 21, 45-78
42. Beer, A. J.; Schwaiger, M. Imaging of integrin alphavbeta3 expression Cancer Metastasis Rev. 2008, 27, 631-644
43. Christofori, G. New signals from the invasive front Nature 2006, 441, 444-450
44. 1 integrins on capillary tube formationin a human fibrinous matrix Angiogenesis 2009, 12, 275-285
45. Witz, I. P. Tumor-microenvironment interactions: dangerous liaisons Adv. Cancer Res. 2008, 100, 203-229
46. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer Nature Rev. Cancer 2006, 6, 392-401
47. Kumar, C. C.; Nie, H.; Armstrong, L.; Zhang, R.; Vijay-Kumar, S.; Tsarbopoulos, A. Chloramine T-induced structural and biochemical changes in echistatin FEBS Lett. 1998, 429, 239-248
48. Gillet, A.; Sanner, M.; Stoffler, D.; Olson, A. Tangible Interfaces for Structural Molecular Biology Structure 2005, 13, 483-491
49. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific LLC: San Carlos, CA; [http://www.pymol.org].